An update on treatment strategies for acromegaly

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 13, 2008, Pages 2273-2280

  Katznelson, Laurence ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acromegaly; Growth hormone; Pegvisomant; Pituitary adenoma; Somatostatin analog

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; LONG ACTING DRUG; OCTREOTIDE; PEGVISOMANT; PLACEBO; PROLACTIN; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADJUVANT THERAPY; ARTHROPATHY; ATHEROSCLEROSIS; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLONOSCOPY; COMMON BILE DUCT STONE; COMORBIDITY; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE DURATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TREATMENT FAILURE; EARLY DIAGNOSIS; GALLSTONE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LIFE EXPECTANCY; LIVER FUNCTION; MICROADENOMA; MORTALITY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PREOPERATIVE CARE; QUALITY OF LIFE; RADIOSURGERY; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SLEEP APNEA SYNDROME; SYSTOLIC DYSFUNCTION; THERAPY DELAY; TRANSSPHENOIDAL SURGERY; TUMOR GROWTH;

ACROMEGALY; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; PROGNOSIS; RECEPTORS, SOMATOTROPIN; SOMATOSTATIN;

EID: 52249102626     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.13.2273     Document Type: Review

References (58)

1. Alexander L, Appleton D, Hall R et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980;12:71-9
2. Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006;91:4769-75
3. Gola M, Doga M, Bonadonna S, et al. Neuroendocrine tumors secreting growth hormone-releasing hormone: pathophysiological and clinical aspects. Pituitary 2006;9:221-9
4. Katznelson L. Diagnosis and treatment of acromegaly. Growth Horm IGF Res 2005;15(Suppl A):S31-5
5. Melmed S. Medical progress: scromegaly. N Engl J Med 2006;355:2558-73
6. Sze L, Schmid C, Bloch KE, et al. Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol 2007;156:321-9
7. Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 1994;121:478-83
8. Colao A, Vitale G, Pivonello R, et al. The heart: an end-organ of GH action. Eur J Endocrinol 2004;151(Suppl 1)S93-101
9. Colao A, Spinelli L, Marzullo P, et al. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab 2003;88:3196-201
10. van der Klaauw AA, Bax JJ, Roelfsema F, et al. Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm IGF Res 2006;16:101-7
11. Matano Y, Okada T, Suzuki A, et al. Risk of colorectal neoplasm in patients with acromegaly and its relationship with serum growth hormone levels. Am J Gastroenterol 2005;100:1154-60
12. Renehan AG, Bhaskar P, Painter JE, et al. The prevalence and characteristics of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 2000;85:3417-24
13. Vasen HF, van Erpecum KJ, Roelfsema F, et al. Increased prevalence of colonic adenomas in patients with acromegaly. Eur J Endocrinol 1994;131:235-7
14. Terzolo M, Reimondo G, Gasperi M, et al. Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. J Clin Endocrinol Metab 2005;90:84-90
15. Delhougne B, Deneux C, Abs R, et al. The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J Clin Endocrinol Metab 1995;80:3223-6
16. Jenkins PJ. Acromegaly and cancer. Horm Res 2004;62(Suppl 1): 108-15
17. Bengtsson BA, Eden S, Ernest I, et al. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988;223:327-35
18. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667-74
19. Swearingen B, Barker FG II, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-26
20. Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 2004;151:439-46
21. Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008;93:61-7
22. Freda PU, Nuruzzaman AT, Reyes CM, et al. Significance of 'abnormal' nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 2004;89:495-500
23. Giustina A, Melmed S. Acromegaly consensus: the next steps. J Clin Endocrinol Metab 2003;88:1913-4
24. Arafat AM, Mohlig M, Weickert MO, et al. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab 2008;93:1254-62
25. Ludecke DK, Abe T. Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations. Neuroendocrinology 2006;83:230-9
26. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 2005;152:379-87
27. Biermasz NR, Dulken HV, Roelfsema F. Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels. Clin Endocrinol (Oxf) 2000;53:321-7
28. Powell JS, Wardlaw SL, Post KD, Freda PU. Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab 2000;85:2068-71
29. Barkan AL, Halasz I, Dornfeld KJ, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 1997;82:3187-91
30. Shih HA, Loeffler JS. Radiation therapy in acromegaly. Rev Endocr Metab Disord 2008;9:59-65
31. Castinetti F, Taieb D, Kuhn JM, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 2005;90:4483-8
32. Jezkova J, Marek J, Hana V. et al. Gamma knife radiosurgery for acromegaly - long-term experience. Clin Endocrinol (Oxf) 2006;64:588-95
33. Landolt AM, Haller D, Lomax N, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg; 1998;88:1002-8
34. Landolt AM, Haller D, Lomax N, et al. Octreotide may act as a radioprotective agent in acromegaly. J Clin Endocrinol Metab 2000;85:1287-9
35. Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90:4465-73
36. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005;90:4405-10
37. Ronchi CL, Varca V, Beck-Peccoz P, et al. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 2006;91:121-8
38. Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 1998;83:2646-52
39. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998;83:374-8
40. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004;61:209-15
41. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46
42. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342:1171-7
43. van der Lely AJ, Hutson RK, Trainer PJ, er al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-9
44. Parkinson C, Burman P, Messig M, Trainer PJ. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 2007;92:190-5
45. Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 2006;154:467-77
46. Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005;365:1644-6
47. Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153:737-40
48. Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007;156:75-82
49. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002;87:4554-63
50. Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006;91:1397-403
51. Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007;66:859-68
52. AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract 2004;10:213-25
53. Colao A, Attanasio R, Pivonello R, et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2006;91:85-92
54. Murray RD, Kim K, Ren SG, et al. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 2004;89:3027-32
55. Holland LJ, van der Hoek J, Feelders R, et al. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J Endocrinol Invest 2005;28:36-42
56. van der Hoek J, de Herder WW, Feelders RA, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004;89:638-45
57. Jaquet P, Gunz G, Saveanu A, et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005;153:135-41
58. Saveanu A, Lavaque E, Gunz G, et al. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 2002;87:5545-52